Justyna Kelly
Directeur des opérations chez POINT Biopharma, Inc. (United States)
Profil
Justyna Kelly is currently the VP-Medical Isotope Development & Operations at POINT Biopharma, Inc. She was previously the Chief Operating Officer at POINT Biopharma Global, Inc. from 2021 to 2023.
Ms. Kelly received her undergraduate and graduate degrees from McMaster University.
Postes actifs de Justyna Kelly
| Sociétés | Poste | Début |
|---|---|---|
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Directeur des opérations | - |
Anciens postes connus de Justyna Kelly
| Sociétés | Poste | Fin |
|---|---|---|
| POIT BIOP | Directeur des opérations | 27/12/2023 |
Formation de Justyna Kelly
| McMaster University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| POIT BIOP | Health Technology |
| Entreprise privées | 1 |
|---|---|
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Commercial Services |
